Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial

Tomas Olsson, Aaron Boster, Óscar Fernández, Mark S Freedman, Carlo Pozzilli, Doris Bach, Ouali Berkani, Markus S Mueller, Tatiana Sidorenko, Ernst-Wilhelm Radue, Maria Melanson, Tomas Olsson, Aaron Boster, Óscar Fernández, Mark S Freedman, Carlo Pozzilli, Doris Bach, Ouali Berkani, Markus S Mueller, Tatiana Sidorenko, Ernst-Wilhelm Radue, Maria Melanson

Abstract

Objective: This double-blind, placebo-controlled, dose-finding phase IIb study evaluated the efficacy and safety of ponesimod, an oral selective S1P1 receptor modulator, for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).

Methods: 464 patients were randomised to receive once-daily oral ponesimod 10, 20 or 40 mg, or placebo for 24 weeks. The primary endpoint was the cumulative number of new T1 gadolinium-enhanced (T1 Gd+) lesions per patient recorded every 4 weeks from weeks 12 to 24 after study drug initiation. Secondary endpoints were the annualised confirmed relapse rate (ARR) and time to first confirmed relapse. Safety and tolerability were also evaluated.

Results: The mean cumulative number of new T1 Gd+ lesions at weeks 12-24 was significantly lower in the ponesimod 10 mg (3.5; rate ratio (RR) 0.57; p=0.0318), 20 mg (1.1; RR 0.17; p<0.0001) and 40 mg (1.4; RR 0.23; p<0.0001) groups compared with placebo (6.2). The mean ARR was lower with 40 mg ponesimod versus placebo, with a maximum reduction of 52% (0.25 vs 0.53; p=0.0363). The time to first confirmed relapse was increased with ponesimod compared with placebo. The proportion of patients with ≥ 1 treatment-emergent adverse events (AEs) was similar across ponesimod groups and the placebo group. Frequently reported AEs with higher incidence in the three ponesimod groups compared with placebo were anxiety, dizziness, dyspnoea, increased alanine aminotransferase, influenza, insomnia and peripheral oedema.

Conclusions: Once-daily treatment with ponesimod 10, 20 or 40 mg significantly reduced the number of new T1 Gd+ lesions and showed a beneficial effect on clinical endpoints. Ponesimod was generally well tolerated, and further investigation of ponesimod for the treatment of RRMS is under consideration.

Trial registration number: NCT01006265.

Keywords: Multiple Sclerosis.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Figure 1
Figure 1
Study design. All patients randomised to ponesimod initially received ponesimod 10 mg (days 1–7). On day 8, patients randomised to receive ponesimod 20 or 40 mg were up-titrated to the 20 mg dose and patients randomised to the 10 mg dose were mock up-titrated. On day 15, patients randomised to receive ponesimod 40 mg were up-titrated to the 40 mg dose; patients randomised to ponesimod 10 or 20 mg were mock up-titrated. Patients randomised to placebo were mock up-titrated on days 8 and 15. Patient numbers are for the all-treated population. FU, follow-up.
Figure 2
Figure 2
Patient flow. †Two patients randomised to the ponesimod 20 mg group did not start treatment due to safety findings that were noted after randomisation (low heart rate and abnormal Holter ECG readings). ‡Respiratory system criteria. §One patient discontinued treatment due to pregnancy, one patient discontinued treatment due to respiratory system criteria.
Figure 3
Figure 3
(A) Cumulative number of new T1 Gd+ lesions detected by magnetic resonance image scanning at weeks 12–24 (per-protocol analysis set). Graph shows mean+SE. The percentage reduction (95%CI) versus placebo is shown for each ponesimod treatment group. (B) Dose–response analysis for the cumulative number of new T1 Gd+ lesions from week 12 to 24 (per-protocol analysis set). Black dots represent the mean value for each dose and grey dots represent the fitted models obtained in the bootstrap process. *p

Figure 4

Kaplan–Meier estimate of the time…

Figure 4

Kaplan–Meier estimate of the time to first confirmed relapse up to week 24…

Figure 4
Kaplan–Meier estimate of the time to first confirmed relapse up to week 24 (all-treated analysis set).

Figure 5

(A) Percentage change from baseline…

Figure 5

(A) Percentage change from baseline in lymphocyte counts up to week 24 (all-treated…

Figure 5
(A) Percentage change from baseline in lymphocyte counts up to week 24 (all-treated analysis set). (B) The group of patients who underwent safety follow-up (discontinued treatment prematurely or did not enter the extension study). FU1, follow-up visit 1 (end of treatment + 7 days); FU2, follow-up visit 2 (end of treatment+30 days).

Figure 6

Mean change from baseline in…

Figure 6

Mean change from baseline in heart rate (bpm) on day 1 (A), day…

Figure 6
Mean change from baseline in heart rate (bpm) on day 1 (A), day 8 (B) and day 15 (C) (all-treated analysis set).
Figure 4
Figure 4
Kaplan–Meier estimate of the time to first confirmed relapse up to week 24 (all-treated analysis set).
Figure 5
Figure 5
(A) Percentage change from baseline in lymphocyte counts up to week 24 (all-treated analysis set). (B) The group of patients who underwent safety follow-up (discontinued treatment prematurely or did not enter the extension study). FU1, follow-up visit 1 (end of treatment + 7 days); FU2, follow-up visit 2 (end of treatment+30 days).
Figure 6
Figure 6
Mean change from baseline in heart rate (bpm) on day 1 (A), day 8 (B) and day 15 (C) (all-treated analysis set).

References

    1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502–17.
    1. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001;22:117–39.
    1. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:69–77.
    1. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402–15.
    1. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387–401.
    1. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293–303.
    1. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098–107.
    1. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087–97.
    1. Bolli MH, Abele S, Binkert C, et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem 2010;53:4198–211.
    1. Piali L, Froidevaux S, Hess P, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther 2011;337:547–56.
    1. Gatfield J, Nayler O. Ponesimod is a potent S1P1 receptor modulator causing efficient receptor internalisation, degradation and functional antagonism (P926). Multiple Sclerosis Journal 2012;18(Suppl 4):422.
    1. Brossard P, Derendorf H, Xu J, et al. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol 2013;76:888–96.
    1. Brossard P, Maatouk H, Halabi A, et al. Ascending multiple-dose study with ponesimod, a selective S1P1 receptor agonist: tolerability, safety, pharmacokinetics, and pharmacodynamics (P110). Clin Pharmacol Ther 2012;91(Suppl 1):S93.
    1. Reyes M, Brossard P, D'Ambrosio D, et al. Mass balance, pharmacokinetics, and metabolism of the selective oral S1P1 receptor modulator ponesimod in humans. Clin Pharmacol Drug Dev 2012;1:219.
    1. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis:2005 revisions to the “McDonald Criteria”. Ann Neurol 2005;58:840–6.
    1. WMA. World Medical Association Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects, 2008.
    1. ICH. Guideline for Good Clinical Practice, 1996.
    1. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124–40.
    1. Kappos L, Gold R, Miller DG, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;372:1463–72.
    1. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–89.
    1. Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics 2005;61:738–48.
    1. Selmaj K, Li DK, Hartnung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised,phase 2 study. Lancet Neurol 2013;12:756–67 .
    1. O'Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894–900.
    1. Novartis Pharmaceuticals Corporation. Prescribing information: GILENYA (fingolimod) capsules. (accessed 28 Jun 2013).
    1. Kovarik JM, Schmouder R, Barilla D, et al. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 2004;44:532–7.
    1. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002;277:21453–7.
    1. Fryer RM, Muthukumarana A, Harrison PC, et al. The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P1) and hypertension (S1P3) in rat. PLoS ONE 2012;7:e52985.
    1. Means CK, Brown JH. Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res 2009;82:193–200.
    1. Keller CD, Rivera Gil P, Tölle M, et al. Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. Am J Pathol 2007;170:281–92.
    1. Sobel K, Menyhart K, Killer N, et al. Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling. J Biol Chem 2013;288:14839–51.
    1. Miron VE, Ludwin SK, Darlington PJ, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 2010;176:2682–94.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅